Eliminate the need for urine Bence Jones Protein testing

KatzmannStudies indicate clearly that if you replace urine Bence Jones Protein tests with serum assays including the Freelite free light chains assay, during the initial investigation for Multiple Myeloma, all patients requiring medical intervention are identified.

"...the use of serum PEL plus FLC provides a simple and efficient initial diagnostic screen for high-tumor-burden monoclonal gammopathies such as MM, WM, and SMM. Urine studies and serum IFE can be ordered more selectively."1

"Urine tests are no longer necessary as part of the screening algorithm for identifying monoclonal gammopathies..."2



Remove the inconvenience and improve your detection rate

Increase your detection rate by including Freelite in your investigation protocol. Freelite in combination with SPE enables sensitive quantification of monoclonal gammopathies at diagnosis without the added complications and difficulties of urine collection and testing.1

The superior sensitivity of Freelite allows measurement down through the normal range allowing more accurate detection of Multiple Myeloma, Light Chain Multiple Myeloma, Nonsecretory Multiple Myeloma, AL amyloidosis and other B cell dyscrasias.3

PatientReduce the impact of patient compliance

Reports of only 40% patient compliance in producing 24-hour urines have been cited.4 Lack of compliance can be due to many factors including renal impairment, embarrassment and inconvenience. Now you can avoid these problems and obtain a sample every time as only a blood sample needs to be collected. Conveniently, you can collect this at the same time as blood is taken for other renal function tests.

 

Efficiency gains in the clinic:

  • Just a simple blood collection
  • No need to chase for urine samples
  • Improve the turnaround time for a patient result4
  • Reduce testing costs1,2
  • Use the same reliable test in your initial evaluation that you use in monitoring

Efficiency gains in the laboratory:

  • No need to chase for urine samples
  • No requirement for storage of large volume samples
  • No time consuming concentration of urine
  • Maximise workflow through automation
  • Reduce hands-on time and release valuable labour resource
  • Assay time of less than 20 minutes
  • Improve the turnaround time for a patient result4
  • Reduce testing costs1,2
  • Use the same reliable test in your initial evaluation that you use in monitoring

 

Initial Investigation Protocol

Evidence for the Investigation Protocol

Clinical Evidence for the Utility of Freelite

 

Serum Free Light Chain Information PackSerum Free Light Chain Information Pack

Click here to order your copy.


 

 

 

 

 


References

  1. Jerry A Katzmann, Robert A Kyle, Joanne Benson et al.

    Screening panels for detection of monoclonal gammopathies

    Clinical Chemistry August 2009; 55(8):1517-1522

    Reference: MKG535 Quantity:

  2. Jerry A. Katzmann, Angela Dispenzieri, Robert A. Kyle, Melissa R. Snyder, Matthew F. Plevak, Dirk R. Larson, Roshini S. Abraham, John A. Lust, L. Joseph Melton III, and S. Vincent Rajkumar.
    "Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays"
    Mayo Clin Proc. 2006;81(12):1575-1578

    Reference: MKG343 Quantity:

  3. A.R. Bradwell
    Serum Free Light Chain Analysis (Plus Hevylite)
    5th edition paperback

    Reference: MKG360 Quantity:

  4. Peter G. Hill, Julia M. Forsyth, Baldeep Rai, and Stewart Mayne
    "Serum Free Light Chains: An Alternative Test to Urine Bence Jones Proteins When Screening for Monoclonal Gammopathies"
    Clin Chem 2006 52: 1743-1748.

    Reference: MKG326 Quantity: